Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. More Details
No risks detected for ALKS from our risk checks.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Alkermes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALKS is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ALKS's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALKS exceeded the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: ALKS underperformed the US Market which returned 50.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Alkermes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
20 hours ago | Simply Wall StAlkermes'(NASDAQ:ALKS) Share Price Is Down 52% Over The Past Three Years.
1 month ago | Simply Wall StAlkermes plc (NASDAQ:ALKS): When Will It Breakeven?
2 months ago | Simply Wall StIs Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Is Alkermes undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALKS ($22.26) is trading below our estimate of fair value ($104.98)
Significantly Below Fair Value: ALKS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALKS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALKS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALKS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALKS's PB Ratio (3.4x) is in line with the US Biotechs industry average.
How is Alkermes forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALKS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ALKS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALKS's is expected to become profitable in the next 3 years.
Revenue vs Market: ALKS's revenue (8% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: ALKS's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALKS's Return on Equity is forecast to be low in 3 years time (17.3%).
How has Alkermes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALKS is currently unprofitable.
Growing Profit Margin: ALKS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALKS is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare ALKS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALKS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).
Return on Equity
High ROE: ALKS has a negative Return on Equity (-9%), as it is currently unprofitable.
How is Alkermes's financial position?
Financial Position Analysis
Short Term Liabilities: ALKS's short term assets ($1.0B) exceed its short term liabilities ($365.8M).
Long Term Liabilities: ALKS's short term assets ($1.0B) exceed its long term liabilities ($461.2M).
Debt to Equity History and Analysis
Debt Level: ALKS's debt to equity ratio (28.3%) is considered satisfactory.
Reducing Debt: ALKS's debt to equity ratio has increased from 27.6% to 28.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALKS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALKS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 36.8% per year.
What is Alkermes's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALKS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALKS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALKS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALKS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALKS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Pops (58 yo)
Mr. Richard F. Pops has been the Chief Executive Officer of Alkermes PLC since September 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc. He was a Co-founder of Sirtris Pharmaceuticals, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD14.64M) is above average for companies of similar size in the US market ($USD5.32M).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
Experienced Management: ALKS's management team is considered experienced (3.2 years average tenure).
Experienced Board: ALKS's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alkermes plc's company bio, employee growth, exchange listings and data sources
- Name: Alkermes plc
- Ticker: ALKS
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.572b
- Shares outstanding: 160.45m
- Website: https://www.alkermes.com
Number of Employees
- Alkermes plc
- Connaught House
- 1 Burlington Road
- Co. Dublin
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ire...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 22:55|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.